- Design
- Systematic review with pairwise and network meta-analysis
- Population
- 992 participants with non-infectious uveitis in 7 studies
- Primary outcome
- Treatment failure
- Effect
- Adalimumab vs placebo RR 0.67 (0.58–0.78)
A systematic review with network meta-analysis pooled seven studies (992 participants; six randomised trials and one prospective cohort) of systemic immunomodulatory therapy for non-infectious uveitis, searched to May 2026.
Adalimumab reduced treatment failure compared with placebo (RR 0.67, 95% CI 0.58 to 0.78), with low heterogeneity (I² = 28%). It increased injection-site reactions (RR 2.67). Three deaths occurred with adalimumab and none with placebo, but the estimate was highly imprecise (RR 3.80, 0.42 to 34.15). Most other safety outcomes did not differ in the network. An infliximab urinary infection signal rested on sparse events and one non-randomised comparison.
The evidence base for comparing agents directly is thin; most data compare adalimumab with placebo. Conventional agents such as methotrexate and mycophenolate are widely used first as steroid-sparing therapy, and this review does not displace that sequence.
What it reinforces is that adalimumab is the best-supported biologic when conventional immunosuppression fails or is unsuitable.
- Consider adalimumab when conventional steroid-sparing therapy fails or is not tolerated.
- Screen for tuberculosis and hepatitis B before starting an anti-TNF agent.
- Warn patients about injection-site reactions.
- Co-manage with rheumatology or uveitis specialists for systemic monitoring.
Why it matters
It confirms where the evidence is strongest when choosing a biologic for sight-threatening uveitis.
Don't overread it
Few head-to-head data; this does not show adalimumab is better than other biologics, only better supported.
The statistics, in plain English
A risk ratio of 0.67 means treatment failure was about a third less likely on adalimumab. The mortality interval from 0.42 to 34 is so wide that it gives no useful information either way.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for ophthalmology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free